Clinical writing on radioligand therapy — and the lives it touches.

Ac-225 PSMA-617 in Chemotherapy-Naive Prostate Cancer

The case for considering Actinium-225 PSMA earlier in the prostate cancer pathway, before patients have exhausted chemotherapy options.

Lu-177 PSMA Therapy — Cost Considerations in India

Cost transparency for patients evaluating Pluvicto-equivalent therapy abroad. What the price actually covers — and where Indian centres genuinely undercut Western pricing.

Everything you need to know about Alpha PSMA Therapy

A definitive primer on Actinium-225 PSMA — mechanism, eligibility, response rates, and how it compares to beta-emitter Lu-177.

An In-Depth look at Prostate Cancer

A comprehensive patient-facing guide to prostate cancer — biology, staging, treatment options, and where nuclear medicine fits into the pathway.

Ac-225 PSMA Therapy for Castration-Resistant Prostate Cancer

How targeted alpha therapy reshapes the treatment calculus for men with mCRPC who have progressed on hormonal and beta-radioligand therapy.

Lu-PSMA Therapy: A Breakthrough in Prostate Cancer Treatment

The clinical case for Lutetium-177 PSMA as standard of care in metastatic prostate cancer — efficacy, evidence base, and where it fits in the pathway.

Lu-177, Ac-225, and Tb-161 Therapy for Prostate Cancer: A Comparative Analysis

When to use beta, when to escalate to alpha, and where Tb-161 fits — a head-to-head comparison framed for treating physicians and informed patients.

Dr. Ishita B. Sen — A Thoughtful Approach to Prostate Cancer Treatment

A profile of Dr. Sen's clinical philosophy — why she favours an iterative, dosimetry-led approach over fixed-protocol thinking.

Raised psa what does it means

PSA is a starting point, not a verdict. What an elevated PSA actually tells your urologist and what comes next.

When Should a Scan be Done to Assess Success of LU PSMA

Imaging timing matters. When to repeat PSMA-PET, when to wait, and how interim scans inform whether to continue or escalate.

How Do You determine if Your Pluvicto Therapy is Working

PSA, imaging, symptoms — three signals, sometimes contradictory. How we read them together to decide whether to continue cycles.

Lu-177 PSMA-617 — Three Anonymised Composite Cases

Three anonymised composite cases walking through PSA trajectory, imaging response, and tolerability over multiple cycles of Pluvicto.

Lutetium 177 PSMA Therapy as the first line of treatment for Metastatic Prostate Carcinoma

The argument — and the evidence — for moving Lu-PSMA earlier in the treatment sequence than the post-chemotherapy positioning it currently holds.

What are the adverse effects of PSMA Therapy

Common, uncommon, and rare side effects of Lu-PSMA and Ac-PSMA — and how we screen for and manage each one.

Lu-177 PSMA Therapy — Published Outcomes from VISION & TheraP

What VISION and TheraP actually reported on Lu-177 PSMA outcomes — median response duration, overall survival benefit, and how to read the data.

Do All Prostate Cancers Express PSMA

PSMA expression is not universal. Why imaging the target before treating it is non-negotiable — and what to do when the tumour doesn't take up the tracer.

Alpha Emitters Are 5 Times More Potent Than Beta Emitters By Dr. Ishita B. Sen

The physics behind why a single Ac-225 alpha decay does more cellular damage than a Lu-177 beta decay — and why 'more potent' isn't always 'better'.

Prostate Cancer Survival After Prostatectomy — 20-Year Outcomes

प्रोस्टेट कैंसर सर्जरी के बाद जीवन प्रत्याशा, जीवन की गुणवत्ता और दीर्घकालिक स्वास्थ्य के बारे में हिंदी में पूरी जानकारी।

Pluvicto Life Expectancy

Median response duration, overall survival benefit, and the difference between 'extending life' and 'curing disease' — explained for families.

Can you live for 20 years after prostate removal?

Long-term outcomes after radical prostatectomy — survival statistics, quality-of-life realities, and what the published data tells us across cohorts.

Prostate Cancer Awareness Month — Screening and Early Detection

Why early detection matters more than any single therapy, and what every man over fifty should be doing about screening.

Prostate Cancer Treatment — A Sourced Patient Pillar Guide

From PSA test to PSMA therapy — every decision point in the prostate cancer treatment pathway, mapped out for newly diagnosed patients.

How India is Becoming a Global Hub for Pluvicto Therapy

Supply-chain logistics, regulatory landscape, and price differential have made India a destination for Pluvicto-equivalent therapy. The honest account of why.

Early Treatment of Prostate Cancer with Lu-177 PSMA Radiotherapy (PRRT)

The evidence behind moving Lu-PSMA earlier in the treatment sequence — PSMAfore, SPLASH, and the patient profiles where earlier intervention may meaningfully improve outcomes.

PRRT for Lung Neuroendocrine Tumors

Bronchial and pulmonary NETs are a distinct PRRT-eligible group. Selection criteria, expected response rates, and the published evidence for this less-discussed indication.

Sequencing treatment in prostate cancer: the logic at every step

Prostate cancer is rarely a single decision. It is a sequence of them, made over years, as the disease changes. This guide explains how doctors think about that sequence — the pros and cons at each step, why the order matters, and how a man’s age and fitness shape every choice — in plain language, grounded in the major trials and guidelines.

Pluvicto (Lu-177 PSMA): success rate, life expectancy and cost

Three questions come up first when a family considers Pluvicto: does it work, how long does it give, and what does it cost? This is a plain, evidence-based answer — the VISION trial survival figures, the PSA response rates, and transparent pricing in both the US and India — with the honest caveats that any of these numbers deserve.

Lu-177 PSMA rechallenge: re-treating after a previous response.

If a man’s prostate cancer responded well to Lu-177 PSMA therapy and then came back, can the same treatment be given again? For carefully selected patients, the answer is often yes. This is a plain, evidence-based guide to who qualifies, how well rechallenge works, and how its safety is managed.

PRRT Treatment Day Overview

What to expect from admission to discharge on a PRRT cycle day — written for patients preparing for their first session.

Lu177 PRRT For Neuroendocrine Tumors (Nets)

The standard-of-care radioligand for somatostatin-receptor-positive NETs — mechanism, indications, and what 4 cycles of DOTATATE actually achieve.

Which Patients can benefit with PRRT?

Eligibility criteria explained — somatostatin receptor expression, disease progression, organ function, and how we triage referrals.

131 Iodine MIBG Therapy For Pediatric Neuroblastoma

How I-131-MIBG is delivered for high-risk and refractory paediatric neuroblastoma — the protocol, the precautions, and the response data.

Alpha PRRT: Advancing the Treatment of Neuroendocrine Tumors (NETs)

Why high-LET alpha radiation matters in micro-metastatic NET disease, and where Ac-225-DOTATATE is changing salvage outcomes.

Lutetium PRRT for Metastatic well-differentiated Neuroendocrine Tumor

Outcomes data from well-differentiated metastatic NETs treated with Lu-177-DOTATATE — what the literature and our cohort show.

NETs Refractory to Chemotherapy — Evidence and Treatment Sequence

The biology of NETs explains why traditional chemotherapy frequently fails — and why receptor-targeted radioligand therapy has become the cornerstone of treatment.

Peptide Receptor Radionuclide Therapy (PRRT): A Comprehensive Clinical Overview

Success rates, response patterns, and the full clinical picture of peptide receptor radionuclide therapy for NETs.

Unlocking Advanced PRRT Combination of PRRT and Chemo for treating Neuroendocrine Tumors

When PRRT alone isn't enough — adding chemotherapy and the patient profile where the combination delivers better tumour control.

Understanding Neuroendocrine Tumors and their symptoms by Dr. Ishita B Sen

From carcinoid syndrome to functional secretion — what NETs look like clinically, and why diagnosis is so often delayed.

PRRT for Pheochromocytoma & Paraganglioma

PPGL tumours overexpress somatostatin receptors — making PRRT a meaningful option for unresectable, metastatic, or progressive cases that have failed standard therapy.

What is the Recovery Time after PRRT?

Cycle-by-cycle recovery realities for PRRT patients — what the first 48 hours feel like, what to watch for in the first two weeks, and what 'back to normal' actually looks like.

PRRT for Lung Neuroendocrine Tumors

Bronchial and pulmonary NETs are a distinct PRRT-eligible group. Selection criteria, expected response rates, and the published evidence for this less-discussed indication.

Ga-68 DOTATATE PET Scan: What to Expect

Step-by-step walkthrough of the Ga-68 DOTATATE PET-CT scan — preparation, what happens on scan day, and how to read the report.

Tb-161 Salvage After Lu-177 PSMA Progression

Cross-resistance, biological plausibility, and what we're learning from the small but growing cohort of Lu-PSMA non-responders treated with Tb-161-PSMA.

Stable Supply of Terbium at our centre ensure timely treatment

How the TPPL–TerThera arrangement guarantees on-schedule Tb-161 cycles for international patients planning multi-cycle courses.

Is Terbium-161 the Next-Gen Alternative to Lutetium-177?

The honest answer is: 'in some patients, yes — but the case is still being built.' What we know now, and what trial data should clarify next.

Terbium-161 Clinical Handbook — Supply, Cycles, Dosimetry & FAQ

The consolidated reference on Tb-161 — supply chain, treatment cycles, dosimetry workflow, comparison with Lu-177, and answers to the questions patients and referring oncologists ask most.

TARE vs TACE for Hepatocellular Carcinoma and NET patients

Comparing transarterial radioembolisation (Y-90) and transarterial chemoembolisation across HCC and neuroendocrine liver metastases — eligibility, outcomes, and selection logic.

Use of Yttrium 90 (Y-90) and its effects

Y-90 microsphere therapy explained — how the radiation is delivered, what side effects to expect, and how outcomes compare to TACE.

What is Transarterial Radioembolization (TARE)

A foundational explainer on TARE for liver tumours — how the catheter-delivered Y-90 microsphere therapy works and who is a candidate.

Transarterial Radioembolization (TARE) as a Treatment for Liver Transplant Candidates

TARE as bridging and downstaging therapy in HCC patients on the transplant list — what the survival data and Milan-criteria conversion rates show.

Yttrium-90 (Y-90) Radioembolization: A Comprehensive Guide for Liver Cancer Treatment

A complete reference on Y-90 TARE — patient selection, mapping angiography, microsphere choice, dosimetry, and post-therapy follow-up.

TARE as Bridge to Liver Transplant in HCC

How Y-90 TARE serves as bridge and downstaging therapy for HCC patients awaiting liver transplant — preserving Milan-criteria eligibility and disease control during the waitlist.

Medical Travel to FMRI India: A Patient Pathway Guide

An international patient's pathway guide to arriving in Gurugram, navigating logistics, and undergoing therapy at FMRI.

Radioligand Therapy Cost Comparison — India vs International

How Lu-PSMA, Ac-225, Y-90 and Tb-161 prices compare across India, the US, Germany, and Australia — and what the differential really represents.

Radio-theranostics: How Tiny Radioactive Molecules are Personalising Cancer Care

The unifying idea behind theranostics — see-and-treat with the same molecular target — and what it means for the future of oncology.

How Nuclear Medicine Is Used in Cancer Diagnosis and Treatment

From diagnostic imaging to targeted therapy, the full arc of nuclear medicine in oncology — written for the curious non-specialist.

Why alpha emitters are about 5× more potent than beta emitters.

The radiobiology behind targeted alpha therapy — high linear energy transfer, the five-to-tenfold relative biological effectiveness of alpha over beta, clustered DNA double-strand breaks, and the very short range that concentrates the killing where it is wanted. With the clinical proof from radium-223 and Ac-225 PSMA. Every figure sourced.

Combating Xerostomia: Botox Shows Promise in Actinium-225 Therapy

Salivary gland protection during alpha-PSMA therapy — what the early Botox-injection studies suggest, and how we counsel patients.

Side effects of Nuclear Medicine Treatment - Overview Lutetium-177, Actinium-225, and Yttrium-90 therapy

A side-by-side comparison of the toxicity profiles across the three major therapeutic isotopes used in radioligand therapy.

PARP inhibitors vs Lu-177 PSMA: how the side effects compare.

Both treat advanced prostate cancer, but they are chosen for different patients — and their side effects differ in kind, not just in degree. This is a plain, factual comparison of the toxicity of the two, with the numbers from the PROfound and VISION trials.

DOTATATE PET Scan — how it works, what it shows

FDG PET Scan — how it works, what it shows

PET scan vs CT scan — what's the difference?

PSMA PET Scan — how it works, what it shows

Bone Scan — how it works, what it shows

Brain PET Scan — dementia, epilepsy, tumours

Gallium Scan — which one do you actually need?

MIBG Scan — how it works, what it shows

Lu-177 PSMA & PRRT: real-world case studies.

Three de-identified patients treated at FMRI Gurugram — two with Lu-177 PSMA therapy for prostate cancer, one with Lu-177 DOTATATE PRRT for a neuroendocrine tumour. We present each case cleanly, with the measured PSA and Chromogranin A responses, and set them beside the published trial evidence so it is clear what is typical and what is not.